DV
K V Dileep
Also known as: Kalarickal vijayan Dileep
RIKEN, RIKEN, Yokohama campus, KS Rangasamy College of Arts and Science, St Thomas College
0000-0002-7456-4226
About
Researcher in Structural biology
Employment
-
RIKEN JSPS Postdoctoral fellow2016 - Present
-
RIKEN International postdoc fellow (Takeda Science Foundation)2016 - 2016
Education
-
RIKEN, Yokohama campus Postdoctoral fellowship2016 - Present
-
KS Rangasamy College of Arts and Science Masters2003 - 2005
-
St Thomas College Bachelors2000 - 2003
Projects & Funding
Projects & funding information is unavailable.
Publications (56)
- Methyl eugenol as a multitarget-directed ligand for Alzheimer disease: A promising lead for drug design Save
- Unravelling the structural impact of progesterone receptor mutations in myoma and progesterone intolerance through computational modeling Save
- Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer Save
- Supplementary Data from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer Save
- Supplementary Figure S1 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer Save
- Supplementary Figure S2 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer Save
- Supplementary Figure S3 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer Save
- Supplementary Figure S4 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer Save
- Supplementary Table S1 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer Save
- Supplementary Table S2 from The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer Save